Table 3.

Cumulative percentage excretion of bendamustine, the metabolites γ-hydroxy-bendamustine, N-desmethyl-bendamustine, and dihydroxy bendamustine, and total radioactivity in urine over 24 hours and total radioactivity in urine and feces over 168 hours and until the end of the collection period following an intravenous 60-minute infusion of 120 mg/m² of ¹⁴C-bendamustine hydrochloride

Collection		Patient						Mean [SD]
		1	2	3	4	5	6
Urine (% excretion)
0–24 hours	Bendamustine	1.46	5.17	1.65	1.85	3.74	5.98	3.31 [1.95]
	M3	0.64	0.36	0.5	0.7	0.76	1.42	0.73 [0.37]
	M4	0	0.12	0.08	0	0	0.27	0.08 [0.11]
	HP2	8.65	4.09	4.18	8.25	2.12	2.04	4.89 [2.9]
	Suma	10.75	9.74	6.41	10.8	6.62	9.71	9.01 [1.99]
	TRA	36.36	36.08	36.53	34.77	32.83	43.1	36.61 [3.47]
0–168 hours	TRA	42.16	50.69	45.26	40.44	43.11	51.11	45.46 [4.49]
0–EoCb	TRA	47.6	57.93	48.26	40.44	47.86	51.93	49 [5.75]
Feces (% excretion)
0–168 hours	TRA	30.3	8.92	34.44	31.88	29.45	16.1	25.18 [10.22]
0–EoCb	TRA	32.64	8.92	34.44	31.88	35.08	18.89	26.98 [10.67]
Total (% excretion)
0–168 hours	TRA	72.46	59.61	79.7	72.32	72.56	67.21	70.64 [6.71]
0–EoCb	TRA	80.24	66.85	82.7	72.32	82.94	70.82	75.98 [6.86]

EoC end of collection period, HP2 dihydroxy bendamustine, M3 γ-hydroxy-bendamustine, M4 N-desmethyl-bendamustine, SD standard deviation, TRA total radioactivity

^aThese values represent the sum of bendamustine, M3, M4, and HP2

^bThe time of the EoC varied among patients and ranged from 168 to 504 hours